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ABSTRACT 
 
             Novel amidino substituted conformationally restricted derivatives of pentamidine 
were synthesized and their antiproliferative activity against several human cancer cell lines 
determinated. It was found that introduction of furandicarboxamide core moiety (9, 10) 
increases antiproliferative activity as well as selectivity against certain tumor cell lines in 
comparison with amidino-substituted furan-mono-carboxamide (5, 6). Unlike the furan series 
where iso-propyl substituted amidine (10) exhibits more potent overall antiproliferative 
activity and selectivity toward certain cell lines, the same was found for unsubstituted 
amidines in pyridine series. Amongst all tested compounds the compound 10 is the only one 
that possesses antiproliferative activity against SW 620 cell line (4 µM). Spectroscopic 
studies of the interactions of prepared diamidines with double stranded DNA and RNA 
polynucleotides show that all compounds preferentially bind into the minor groove of DNA, 
while most of them intercalate into RNA. The structure-dependant biological activity and the 
lack of DNA/RNA selective binding suggest that the mechanism of action of the here-
presented compounds is controlled not only by the interactions with cellular nucleic acids, but 
also with other more specific protein targets. 
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 1. Introduction 
 
The design of small molecules that target the minor groove of double helix of B-DNA 
has been of great interest for the development of new therapeutics for various diseases [1]. In 
the past few decades various minor groove binding dibenzamidines were found to possess 
antifungal, antileishmanial, antiplasmodial, antitrypanosomal and anti-Pneumocystis carinii 
activity [2,3]. In spite of the broad spectra of biological activities they exhibit, pentamidine is 
the only compound of this class that has been clinically used in humans. It is used against 
early stage human African trypanosomiasis, antimony-resistant leishmaniasis and for P. 
jiroveci pneumonia (PCP) in the treatment of AIDS patients [4]. However, despite its clinical 
usefulness it exhibits a number of serious adverse effects [5]. Results from previous studies 
suggest that the electronic and conformational nature of the linker may influence not only the 
chemical properties of the amidine moieties but also improve biological activity of the 
pentamidine derivatives [6]. Amongst those, furamidine, a bis-amidine diphenylfuran, 
displayed significant anti-PCP and antiprotozoal activities [7], its amidoxime prodrug 
currently being in Phase III trials against PCP.  
In addition to their antimicrobial activities, pentamidine possess cytotoxic activity 
towards various human cancer cell lines [8] and is currently in Phase II clinical trials against 
refractory melanoma. A series of cyclic dibenzoamidines with triazine and carbazole linkers 
[9] as well as furamidine derivatives characterized by different structural features have also 
displayed activities against broad tumor cell line panels [10,11]. 
One of the studied linkers was poorly electrondonating, conformationally restricted 
amide group. Amidinophenyl substituted benzo and pyridine dicarboxamides were prepared 
and tested for their antimicrobial activity or cytotoxic activity against several human cancer 
cell lines [12-15]. Although they showed moderate activity against P. carinii and Plasmodium 
falciparum, their poor antitumor activity was poor [6,14,16]. 
In an attempt to investigate further the antitumor potential of carboxamide linked 
pentamidine derivatives we decided to prepare a series of novel dibenzamidines with various 
aromatic carboxamide linkers and amidino substituents. Amidino- and iso-propylamidino-
substituted pentamidine derivatives with furan-2,5-di-yl-carboxamide and pyridine-2,6-di-yl-
carboxamide linkers were prepared. In order to examine the influence of inverted amide bond 
pattern on biological activity, diamidinobenzoyl-pyridine-2,6-di-yl-amines were also 
synthesized (Figure 1.). Since it was proposed that pentamidine derivatives exert, at least 
partly, their biological activity through DNA binding, the in vitro anti-tumor activity of the 
newly prepared compounds was evaluated and polynucleotide binding studies were conducted 
to determine whether they correlate to the in vitro biological activity. 
Recently, working in the field of benzothieno and thienothienoquinolones, new 
intercalators with antiproliferative activity, we described the synthesis of a number of their 
precursors, cyano and amidino substituted 3-chlorobenzo[b]thiophene- [17], thieno[2,3-b]- 
and thieno[3,2-b]thiophene-2-carboxanilides [18] which were found to exhibit interesting 
antiproliferative properties themselves. They were found to bind to polynucleotides in a weak 
nonintercalative way, and the mechanism of their antiproliferative activity is currently under 
investigation. In order to investigate the influence of different heterocyclic moieties of 
amidino and cyano substituted carboxanilides on their biological activity, furan moiety was 
introduced instead of benzothiophene and thienothiophene groups (Figure 1.).  
 
Figure 1. 
 
 
 
2. Results and discussion  
2.1. Chemistry          
 
Compounds 3, 5, 6 and 9-11 were synthesized according to the procedures shown in 
Scheme 1. Precursor 3 for the synthesis of compounds 5 and 6 was prepared by condensation 
of 2-furoyl-chloride 1 and 4-amino-benzonitrile 2 in the presence of triethylamine. Modified 
procedure was used for the synthesis of the cyano-substituted amides 11 and 17. Cyano-
substituted carboxamide 3 was converted to the corresponding amidines under the Pinner 
conditions [17]. Treatment of 3 with dry HCl gas in anhydrous EtOH gave the imidate ester, 
which was than treated with dry ammonia gas to produce amidino-substituted 2-furan-
carboxamide 5, or with excess of iso-propylamine to give iso-propylamidino substituted 
carboxamide 6. Crude compounds were, after crystallization, isolated as hydrochloride salts. 
Amidino compound 5 was also prepared by condensation of 2-furoyl-chloride 1 with 
corresponding 4-amino-benzamidine hydrochloride 4. No significant difference in the yields 
was observed between linear and convergent method of the synthesis for compound 5.  
    
Scheme 1. 
 Since the solubility of dicyano-substituted furan-2,5-di-yl-carboxamide 11 was too 
low to use Pinner reaction, diamidines 9 and 10 were prepared by direct condensation of the 
corresponding diacyl-chloride 7 with appropriate amino-benzamidines (Scheme 1). The same 
approach was used for the synthesis of 4-amidino-substituted pyridine-2,6-di-yl-carboxamides  
13 and 14 (Scheme 2), giving, in the case of 13, yields similar to those reported by Tao et al 
[6] for the synthesis of the same compound from the corresponding 4-cyanophenyl substituted 
pyridine-2,6-di-yl-carboxamide. Attempts to synthesize amidino-substituted aminopyridines 
18 and 19 by direct condensation of diaminopyridine 15 and amidino-substituted benzoyl 
chlorides failed and they were synthesized from cyano-substituted carboxamide 17 obtained 
by condensation of cyano substituted benzoylchloride 16 with diaminopyridine 15. 
Compound 17 was converted to the corresponding amidines 18 and 19 under the Pinner 
conditions (Scheme 2). 
 
Scheme 2. 
 
      
      
2.2. Interactions of compounds 9, 10, 13, 14, 18 and 19 with double-stranded 
polynucleotides  
 
Many aromatic diamidines are strong DNA minor groove binders, and some evidence 
suggests that groove binding is at least in part responsible for their biological activity [19]. 
Therefore, interactions of novel amidino-substituted dicarboxamides 9, 10, 13, 14, 18 and 19 
with model double-stranded DNAs and RNAs were studied by a series of spectrophotometric 
methods under biologically relevant conditions (pH = 7, sodium cacodylate buffer, I = 0.05 
M). For comparison, interactions of their shorter amidino-substituted analogues 5 and 6 were 
also studied.  
Aqueous solutions of amidino-substituted compounds were initially studied by 
electronic absorption (UV/Vis). Under the experimetal conditions used the absorbance 
intensities were proportional to their concentrations. 
Introduction of the second N-4-amidino-substituted phenylcarbamoyl group to the 
position 5 of 2-furan-carboxamide system (9, 10) resulted in batochromic shift and increased 
 values (approximately doubled) (Table 1). Substitution of furan core group with the 
pyridine one (13, 14) caused a significant decrease of both max and  values, while reversing 
of an amide bond motif (18, 19) resulted in the appearance of the second absorption band with 
lower max (~235 nm). 
 
Table 1. 
 
2.2.1. Thermal denaturation experiments 
 
Relative affinity of studied diamidines toward ds-DNA and ds-RNA were evaluated 
by thermal denaturation experiments at different ratios r ([compound]/[polynucleotide]). Melting 
temperatures (Tm) of polynucleotides were determined from melting curves (Table 2, Figure 
2 and Supp. Info.). 
 
Table 2. 
 
            Since amidino-substituded amides 5 and 6 did not stabilize double helix of ct-DNA, 
further experiments with those compounds were not conducted. 
In general, diamidines moderately stabilize ct-DNA double helix at the ratio r = 0.3 
with the Tm values ranging from 5.6 to 13.5 °C, whereby the highest values were obtained 
for amidinobenzoyl pyridine-2,6-di-yl-carboxamides (18, 19). Only slightly increased 
stabilization of ct-DNA at r = 0.5 points toward saturation of binding sites close to ratio r = 
0.3. All studied compounds stabilized poly dA-poly dT significantly stronger than ct-DNA, 
which is consistent with the observation that pentamidine derivatives prefer AT-rich DNA 
sequences [20]. As in the case of ct-DNA increase of ratio r from 0.3 to 0.5 yielded only 
negligible increase of stabilization effect, suggesting saturation of binding sites close to r = 
0.3.  
 
Figure 2. 
 
Addition of diamidines to the poly A-poly U resulted in markedly weaker stabilization 
at r = 0.3 compared to ct-DNA, with the iso-propylamidine derivatives (10, 14, 19) exhibiting 
somewhat higher stabilization of RNA (poly A-poly U) in comparison to other tested 
compounds. Surprisingly, compounds 10 and 18, and to some extent 19, stabilized ds-RNA at 
ratio r = 0.5 significantly stronger than at ratio r = 0.3, which suggested change of binding 
pattern, possibly due to staked dimmers formation within the RNA major groove. 
 
2.2.2. UV spectroscopy 
 
In order to determine stability and stoichiometry of diamidine-polynucleotide 
complexes, UV titrations were performed. The UV spectra of compounds in the most cases 
resulted in marked changes upon addition of studied polynucleotides, exhibiting strong 
hypochromic effects and in some cases measurable batochromic shifts of the UV maximum of 
a compound. However, spectroscopic changes were mostly observed at excess of a compound 
over polynucleotide concentrations and consequently significant deviations from isosbestic 
points were observed (Figure 3a), suggesting mixed binding modes. Therefore it was not 
possible to process the titration data by means of the Scatchard equation [21] to determine the 
affinity of studied compounds toward polynucleotides. 
  
Figure 3. 
 
           An exception was the UV titration of 10 with ct-DNA (Figure 3b), in which the 
isosbestic point was preserved and processing of the titration data by means of the Scatchard 
equation [21] gave binding constant of Ks = 6.3 x 10
4 M-1. 
 
2.2.3. Ethidium bromide displacement assays  
 
Since studied diamidines do not exhibit fluorescence, the affinities toward 
polynucleotides were determined by ethidium bromide (EB) displacement assay as previously 
described [22]. This technique, based on the quenching of the fluorescence of the ethidium 
bromide-polynucleotide complex upon EB displacement by a competitive compound, has also 
been used to estimate the affinity of ligands that bind to the DNA minor groove. Although EB 
displacement assay can be used for various polynucleotides, the obtained IC50 values cannot 
be directly compared since EB exhibits variable binding stoichiometries and affinities towards 
different nucleic acids. 
Addition of all tested diamidines quenched the fluorescence of EB-polynucleotide 
complexes (Figure 4, Table 3). Obtained IC50 values suggest that studied compounds possess 
similar capacity for displacing EB from its complex with ct-DNA, with the exception of 
compound 9 whose IC50 suggests somewhat stronger affinity towards ct-DNA. Of all tested 
polynucleotides, the highest IC50 values were obtained for displacement of EB from its poly 
dA-poly dT complex, which is in agreement with the highest ΔTm values and the observation 
that pentamidine analogues prefer AT-rich DNA sequences. 
 
Figure 4. 
 
Table 3. 
 
2.2.4. Circular dichroism spectroscopy 
 
Circular dichroism (CD) spectropolarimetry offers useful information on 
conformational changes of the polynucleotide upon ligand binding as well as on the binding 
mode of studied ligands. Upon binding to asymmetric environment achiral compounds can 
show induced CD signals which are characteristic for the binding mode. For instance, DNA 
minor groove binders will exhibit large positive ICD signals in the ligand absorption region, 
while intercalators are characterized by weak ICD signal, which can be either positive or 
negative depending on the orientation of compounds longer axis in respect to the longer axes 
of adjacent basepairs [23]. The studied compounds are not chiral and therefore do not possess 
CD spectrum. 
Experimental conditions used for CD experiments were similar to those used for UV 
titrations which showed mixed binding modes. Clear deviations from the isoelliptic point 
observed in CD spectra upon the subsequent additions of 9, 10, 13, 14, 18, and 19 to different 
polynucleotides clearly support formation of several different types of complexes (Figure 5 
and Supp. Info.).  
Under the conditions of a large excess of ds-DNA (ct-DNA and poly dA-poly dT) over 
compound (r = 0.1) a strong positive ICD band appeared at  = 300 - 330 nm accompanied by 
significant decrease of intensity of ds-DNA CD bands (Figure 5).  
 
Figure 5.  
 
Further increase of compound concentration up to r = 0.3 did not induce significant 
changes, but at ratios r > 0.5 ICD bands strongly changed (ICD band maximum was blue 
shifted in the case of ct-DNAor in the experiments with poly dA-poly dT intensity of ICD 
band decreased) due to the formation of a different type of a complex with ds-DNAs (Figure 
5). Such a dependence of an ICD band on a ratio r suggests that at the excess of DNA over 
compound (up to r = 0.3) molecules predominantly bind into minor groove of DNA, while at 
the excess of compound over DNA, the surplus of small positively charged molecules is either 
stacked along negatively charged DNA backbone or forms dimmers within DNA minor 
groove. The latter possibility is supported by strong bisignate exciton ICD bands at  > 300 
nm observed in several cases, which could be attributed to ligand-ligand stacked dimmers 
positioned within DNA grooves [24,25]. 
At variance to the experiments with ds-DNAs, the addition of compounds 9, 10, 13, 
14, 18, and 19 to the solution of poly A-poly U at the ratio r < 0.3 yielded appearance of a 
weak or moderate negative ICD band in the  = 300 – 330 nm region. Weak negative ICD 
bands were observed for compounds 13 (303 nm) and 19 (299 nm), while 18 exhibits no 
observable ICD. At low [10] / [poly A-poly U]  ratios (r = 0.1), the induced ICD signal in the 
region above 290 nm was small and negative, but at higher ratios (r = 0.2-0.3) it assumed 
bisignate pattern (positive at 306 nm and negative at 333 nm) which might result from exciton 
coupling (aggregation of the ligand molecules and association of these aggregates with the 
polynucleotide) [24,25]. Intriguingly, compound 10 stabilized ds-RNA significantly stronger 
at r = 0.5 than at r = 0.3, which could also be attributed to stacked dimmer formation within 
RNA major groove at r > 0.3. Negative signal, however, disappears with further addition of 
10 and at the ratio of r = 0.7 gives positive ICD at 326 nm. There were marked changes in the 
CD signals of poly A-poly U as well. The positive CD bands (266 nm and 222 nm) decreased 
in intensity, while a negative band (244 nm) increased. Experiments with poly G-poly C 
resulted in the similar effects. Changes observed in CD signals of ds-RNA polynucleotides 
suggest that 9, 10, 13, 14, 18, and 19 cause significant conformational changes in ds-RNA 
accompanied by weak negative ICD bands at low ratios r (excess of the RNA over 
compound), which is in the agreement with intercalative binding mode [23]. Again, at excess 
of compound over polynucleotide (r > 0.3) further changes in CD spectra were observed due 
to the agglomeration of small molecule surplus along polynucleotide.  
  
2.3. Cytotoxic activity 
 
Compounds 3, 5, 6, 9-11, 13, 14, 18 and 19 were tested for their potential 
antiproliferative effect on a panel of 5 human cell lines which were derived from 5 cancer 
types: Hep-2 (laryngeal carcinoma), HeLa (cervical carcinoma), MiaPaCa-2 (pancreatic 
carcinoma), SW 620 (colon carcinoma), and MCF-7 (breast carcinoma). Compounds 13, 14, 
18 and 19 were additionally tested on MOLT-4 (lymphoblastic leukemia), HCT 116 (colon 
carcinoma), and H 460 (lung carcinoma) human cancer cells. 
All tested compounds showed certain antiproliferative effect (Table 4 and Table 5). 
Unlike their benzothiophene and thienothiophene anilide analogues, the cyano- and amidino- 
monosubstituted compounds 3, 5 and 6 exhibited no antiproliferative activity producing only 
modest growth inhibition against HeLa or MCF-7 lines, predominantly at the highest tested 
concentration, pointing towards the importance of benzothiophene and thienothiophene 
moieties for the antiproliferative activity of that class of compounds [17,18].  
 
Table 4. 
 
Table 5. 
 
On the other hand, prolongation of the amido-scaffold (9, 10) resulted in markedly 
stronger antiproliferative effect towards certain cell lines, especially MCF-7. 
Isopropylamidino-substituted compound 10 exhibits somewhat stronger antiproliferative 
activity than its amidino-substituted analogue 9. Compound 10 had the strongest 
antiproliferative effect towards the MCF-7 (4 µM) and SW620 (4 µM) cell lines. The weakest 
effect was observed for dicyano-substituted compound 11, which produced no growth 
inhibition, even at the highest tested concentrations, indicating the influence of the amidino-
substituents on antiproliferative activity in the series of the disubstituted furans. Unlike furan 
diamidines, pyridine diamidines (13, 14, 18, 19) exhibited only moderate antiproliferative 
activity to some of the tested cell lines.  
 
3. Conclusions 
 
New conformationally restricted derivatives of pentamidine with arylcarboxamide 
linkers were synthesized and characterized. The antitumor activities of newly prepared 
compounds were evaluated on several different human cancer cell lines. Compounds with 
furandicarboxamide moiety exhibited antiproliferative activity in low micromolar 
concentration range (9 and 10). At the same time introduction of furandicarboxamide linker 
strongly influenced the selectivity towards certain cell lines (Hep-2, SW 620 and MCF-7). 
The effect is less pronounced for pyridinedicarboxamide and diaminopyridine compounds 
(13, 14, 18, 19) and they possess only moderate antiproliferative activities against some cell 
lines. Substitution of amidino groups by iso-propyl moiety in general increased the 
antiproliferative activities of furandicarboxamide derivatives. Unlike furane order, the 
antiproliferative activity and selectivity of the pyridine order is more pronounced for 
unsubstituted amidines (13, 18). In addition, of all tested compounds only the compound 10 
exerted antiproliferative activity against SW 620.  
In contrast to the structure-sensitive biological activity, no significant differences in 
DNA/RNA binding were observed concerning the heterocylic core or the nature of amidino-
substituents. Namely, spectroscopic analysis of compounds/ds-polynucleotides interactions 
showed that all tested compounds bind as groove binders to ct-DNA and poly dA-poly dT, 
while on the other hand they most probably intercalate into RNA double helices (poly A-poly 
U, poly G-poly C). Therefore, we assume that the mechanism of action of the here-presented 
compounds is controlled not only by the interaction with cellular nucleic acids, but also with 
other more specific protein target. Further experiments are needed in order to provide more 
details on the mechanism of their biological activity and selectivity towards different cell 
lines. 
 
 
 
 
 
 
 
 
4. Experimental protocol 
 
4.1. Chemistry 
4.1.1. General methods 
 
 Melting points were determined on a Kofler hot-stage microscope and are uncorrected. 
IR spectra were recorded on a Nicolet Magna 760 spectrophotometer in KBr discs. 1H and 13C 
NMR spectra were recorded on either a Bruker Avance DPX 300 spectrometer using TMS as 
an internal standard in DMSO-d6, CDCl3 or CD3OD. Elemental analysis for carbon, hydrogen 
and nitrogen were performed on a Perkin-Elmer 2400 elemental analyzer. All compounds 
were routinely checked by thin layer chromatography (TLC) with precoated Merck silica gel 
60F-254 glass plates and the spots were detected under UV light. 
           
4.1.2. General procedure A: Synthesis of cyano substituted carboxamides  
To a solution of carbonyl chloride (dry toluene or dry DMF) was added dropwise a solution of 
appropriate amine (dry THF or dry toluene) or a solution of 4-aminobenzonitrile (toluene), 
followed by the addition of Et3N. The mixture was refluxed for 1.5 h-14 h. After cooling, 
precipitated crystals were filtered off, washed with diluted HCl and water, and recrystallized. 
 
4.1.3. General procedure B: Synthesis of amidino substituted carboxamides 
To a solution (dry DMF) or a suspension (dry toluene) of N-isopropyl 4-amino-benzoamidine 
hydrochloride or 4-amino-benzoamidine hydrochloride was added dropwise a solution of 
appropriate carbonyl chloride (dry toluene or dry THF), followed by the addition of Et3N. The 
mixture was refluxed for 2.5 h-2 days. After cooling, the solution was concentrated and 
precipitated crystals were filtered off and washed with diluted HCl and water. Dry HCl was 
bubbled into a suspension of a crude product in dry ethanol (40 ml) and stirred overnight. 
Precipitate was filtered off and recrystallized. 
4.1.4. General procedure C: Synthesis of amidines from the corresponding nitriles  
Dry HCl gas was bubbled for 4 h into a cooled suspension (00C) of nitrile compound in 
anhydrous ethanol. The suspension was stirred at room temperature until the –CN band was 
undetectable (IR). After anhydrous diethyl ether was added, the corresponding imidate ester 
was collected by filtration. The product was suspended in anhydrous ethanol and the 
corresponding amine was added. For the synthesis of unsubstituted amidines, the suspension 
was treated with anhydrous ammonia gas and stirred for 3 days at room temperature. For the 
synthesis of isopropyl-substituted amidines, excess of isopropylamine (2 molar equivalents) 
was added to a suspension of imidate ester. Solvent was removed by evaporation and dry 
diethyl ether was added. Obtained solid was treated with saturated HCl-EtOH solution (40 
ml). Recrystallization from appropriate solvents gave pure amidines as hydrochloride salts.  
 
 4.1.5. N-(4-Cyanophenyl)-furan-2-yl-carboxamide (3) 
 Following the general procedure A, from 2 (9.96 g, 0.084 mol) in dry toluene (260 ml), 1 
(7.54 ml, 0.076 mol) in dry toluene (10 ml), and Et3N (10 ml, 0.17 mol), after refluxing for 
1.5 h and recrystallization from chloroform: 14.3 g (88%) of light-brown powder was 
obtained, mp 176-178 0C; IR (KBr) (νmax/cm-1): 2220, 1670, 1580; 1H NMR (CDCl3) (δ ppm): 
8.28 (s, 1H, Hamide) 7.79 (d, 2H, J = 8.46 Hz, Harom.) 7.64 (d, 2H, J = 8.71 Hz, Harom.) 7.54 (s, 
1H, Hfuran5) 7.29 (d, 1H, J = 3.33 Hz, Hfuran3) 6.59 (dd, 1H, J1 = 3.33 Hz, J2 = 1.54 Hz, Hfuran4); 
13C NMR (CDCl3) (δ ppm): 158.9, 156.0, 147.9, 145.8, 145.4, 131.8, 125.9, 126.7, 121.1, 
120.8, 117.5, 112.5; Anal. (C12H8N2O2) Calcd.: C, 59.00; H, 3.30; N, 11.47; Found: C, 59.06; 
H, 3.39; N, 11.46.             
 
4.1.6. N-(4-Amidinophenyl)-furan-2-yl-carboxamide hydrochloride (5) 
 Method A.: following the general procedure B, from 4 (1 g, 0.0074 mol) in dry toluene (85 
ml), 1 (0.58 ml, 0.0059 mol) in dry toluene (10 ml), and Et3N (1.5 ml, 0.012 mol), after 
refluxing for 18 h and recrystallization from ethanol: 0.38 g (19%) of white powder was 
obtained,. mp 258-262 0C; IR (KBr) (νmax/cm-1): 3328, 3121, 1694; 1H NMR (DMSO-d6) (δ 
ppm): 10.76 (s, 1H, Hamide) 9.33 (s, 2H, Hamidine) 9.12 (s, 2H, Hamidine) 8.03 (d, 2H, J = 8.87 Hz, 
Harom.) 7.989-7.995 (m, 1H, Hfuran5) 7.86 (d, 2H, J = 8.84 Hz, Harom.) 7.56 (d, 1H, J = 3.46 Hz, 
Hfuran3) 6.730-6.747 (m, 1H, Hfuran4); 
13C NMR (DMSO-d6) (δ ppm): 158.2, 149.6, 139.1, 
137.8, 135.8, 120.6 (2C), 114.8, 112.1 (2C), 107.7, 104.1; Anal. (C12H12ClN3O2 x H20) 
Calcd.: C, 51.18; H, 4.97; N, 14.81; Found: C, 50.99; H,5.18; N,14.81.  Method b.: following 
the general procedure C, from 3 (1.51 g, 0.0071 mol) and after recrystallization from water: 
0.263 g (14%) of white crystals.   
 
4.1.7. N-[4-(N’-Isopropylamidino)phenyl]-furan-2-yl-carboxamide hydrochloride (6) 
Following the general procedure C, from 3 (1.0 g, 0.0047 mol) and after recrystallization from 
methanol: 0.41 g (28%) of white crystals. was obtained,  mp 292-296 0C;   IR (KBr) (νmax/cm-
1): 3117, 2969, 2854, 1678, 1666, 1621; 1H NMR (DMSO-d6) (δ ppm): 10.72 (s, 1H, Hamide) 
9.48 (d, 1H, J = 7.98 Hz, Hamidine) 9.37 (s, 1H, Hamidine) 9.04 (s, 1H, Hamidine) 8.01 (d, 2H, J = 
8.31 Hz, Harom.) 7.98 (s, 1H, Hfuran5) 7.73 (d, 2H, J = 8.64 Hz, Harom.) 7.54 (d, 1H, J =3.33 Hz, 
Hfuran3) 6.728-6.739 (m, 1H, Hfuran4) 4.02-4.09 (m, 1H, CHi-pr) 1.26 (d, 6H, J = 6.32, 2CH3 i-pr); 
13C NMR (CD3OD) (δ ppm): 164.4, 159.2, 148.8, 147.5, 144.8, 130.2 (2C), 125.9, 121.8 
(2C), 117.3, 113.7; Anal. (C15H18ClN3O2) Calcd.: C, 58.53; H, 5.89; N, 13.65; Found: C, 
58.23; H, 5.89; N, 13.41.   
 
4.1.8. N,N’-Di-(4-amidinophenyl)-(furan-2,5-di-yl)-carboxamide hydrochloride (9) 
 Following the general procedure B, from 4 (1.23 g, 0.0091 mol) in dry DMF (150 ml), 7 (0.8 
g, 0.0041 mol) in dry THF (30 ml), and Et3N (2.8 ml, 0.02 mol), after refluxing for 15 h and 
recrystallization from water: 0.37 g (19.6 %) of white powder was obtained,. mp >300 0C; IR 
(KBr) (νmax/cm-1): 3300, 1660, 1600; 1H NMR (DMSO-d6) (δ ppm): 11.81 (s, 2H, Hamide) 9.27 
(s, 4H, Hamidine) 8.95 (s, 4H, Hamidine) 8.32 (d, 4H, J = 8.31 Hz, Harom.) 7.83 (d, 4H, J = 8.31 Hz, 
Harom.) 7.46 (s, 2H, Hfuran); 
13C NMR (DMSO-d6) (δ ppm): 164.9 (2C), 156.0 (2C), 148.2 
(2C), 143.7 (2C), 129.0 (4C), 122.8 (2C), 120.1 (4C), 117.4 (2C); Anal. (C20H20Cl2N6O3 x 
3H2O) Calcd.: C, 46.43; H, 5.06; N, 16.34; Found: C, 46.75; H, 5.08; N, 16.70.   
 
4.1.9. N,N’-Di-[4-(N’’-isopropylamidino)phenyl]-(furan-2,5-di-yl)-carboxamide 
hydrochloride (10)  
Following the general procedure B, from 8 (2.21 g, 0.012 mol) in dry toluene (150 ml), 7 (1.0 
g, 0.0052 mol) in dry toluene (50 ml), and Et3N (0.9 ml, 0.006 mol), after refluxing for 14 h 
and recrystallization from ethanol: 0.52 g (18.3 %) of white powder. was obtained,.  mp >300 
0C;  IR (KBr) (νmax/cm-1): 3241, 3058, 2975, 2932, 1697, 1670, 1619; 1H NMR (DMSO-d6) (δ 
ppm): 11.87 (s, 2H, Hamide) 9.48 (d, 2H, J = 7.64 Hz, Hamidine) 9.47 (s, 2H, Hamidine) 9.01 (s, 2H, 
Hamidine) 8.33 (d, 2H, J = 7.64 Hz, Harom.) 7.72 (d, 4H, J = 8.65 Hz, Harom.) 7.44 (s, 2H, Hfuran) 
4.03-4.07 (m, 2H, J = 6.35 Hz, CHi-pr) 1.25 (d, 12H, J = 6.32 Hz, CH3 i-pr); 
13C NMR (DMSO-
d6) (δ ppm): 161.4 (2C), 156.0 (2C), 148.3 (2C), 143.2 (2C), 129.1 (4C), 124.0 (2C), 120.1 
(4C), 117.4 (2C), 45.0 (2C), 21.4 (4C); Anal. (C26H32Cl2N6O3 x H2O) Calcd.: C, 55.22; H, 
6.06; N, 14.86; Found:  55.41; H, 6.18; N, 14.98.   
 
4.1.10. N,N’-Di-(4-cyanophenyl)-(furan-2,5-di-yl)-carboxamide (11)  
Following the general procedure A, from 7 (1.0 g, 0.0052 mol) in dry toluene (130 ml), 2 
(1.22 g, 0.0103 mol) in dry toluene (30 ml), and Et3N (3.5 ml, 0.025 mol), after refluxing for 
14 h and recrystallization from the mixture of DMF and water (1:1): 0.24 g (12.7%) of white 
powder. was obtained,.  mp >300 0C; IR (KBr) (νmax/cm-1): 2220, 1670, 1590; 1H NMR 
(DMSO-d6) (δ ppm): 10.71 (s, 2H, Hamide) 7.985 (d, 4H, J = 8.75 Hz, Harom.), 7.87 (d, 4H, J = 
8.73 Hz, Harom.) 7.55 (s, 2H, Hfuran); 
13C NMR (DMSO-d6) (δ ppm): 155.8 (2C), 148.1 (2C), 
142.4 (2C), 133.3 (4C), 120.3 (4C), 118.9 (2C), 116.8 (2C), 105.9 (2C); Anal. (C20H12N4O3) 
Calcd.: C, 67.39; H, 3.39; N, 15.73; Found: C, 67.47; H, 3.52; N, 15.81.  
 
4.1.11. N,N’-Di-(4-amidinophenyl)-(pyridine-2,6-di-yl)-carboxamide hydrochloride (13) 
Following the general procedure B, from 4 (0.8 g, 0.0059 mol) in dry DMF (100 ml), 12 (0.57 
g, 0.0028 mol) in dry THF (40 ml), and Et3N (1.4 ml, 0.010 mol), after refluxing for 48 h and 
recrystallization from methanol: 0.88 g (66%) of white powder. was obtained,.  mp. > 3000C 
(lit.6 = 3180C); 1H-NMR (DMSO-d6) (δ ppm): 11.79 (s, 2H, Hamide), 9.34 (s, 4H, Hamidine), 9.07 
(s, 4H, Hamidine), 8.415 (d, 2H, Hpy, J = 7.32 Hz), 8.33 (d, 5H, 4Harom., 1Hpy, J = 8.64 Hz), 7.91 
(d, 4H, Harom., J = 8.65 Hz). 
 
4.1.12. N,N’-Di-[4-(N''-isopropyl)amidinophenyl]-(pyridine-2,6-di-yl)-carboxamide 
hydrochloride (14) 
 Following the general procedure B, from 8 (1.5 g, 0.0085 mol) in dry DMF (100 ml), 12 
(0.86 g, 0.0042 mol) in dry THF (50 ml), and Et3N (3 ml, 0.022 mol), after refluxing for 48 h 
and recrystallization from ethanol: 1.25 g (53 %) of white powder. was obtained mp 238-
2420C; IR (KBr) (νmax/cm-1): 3200, 3020, 1650, 1600; 1H-NMR (DMSO-d6) (δ ppm): 11.91 
(s, 2H, Hamide), 9.54 (d, 2H, Hamidine, J = 7.68 Hz), 9.43 (s, 2H, Hamidine), 9.08 (s, 2H, Hamidine), 
8.28-8.41 (m, 7H, 4Harom., 3Hpy), 7.79 (d, 4H, Harom., J = 8.97 Hz), 4.05-4.07 (m, 2H, CHi-pr), 
1.27 (d, 12H, CH3 i-pr, J = 6.32 Hz); 
13C-NMR (DMSO-d6) (δ ppm): 162.8, 161.3, 149.1, 
143.1, 139.9, 129.1, 126.0, 124.0, 120.6, 45.1, 21.4; Anal. (C27H33Cl2N7O2 x 3H2O) Calcd.: 
C, 52.94; H, 6.41; N, 16.01. Found: C, 52.59; H, 6.85; N, 16.20. 
  
4.1.13. N,N'-Di-(4-cyanobenzoyl)-(pyridine-2,6-di-yl)-amine (17)  
Following the general procedure A, from 16 (2.96 g, 0.0018 mol) in dry toluene (50 ml), 15 
(0.72 g, 0.0071 mol) in dry THF (50 ml), and Et3N (6.6 ml, 0.090 mol), after refluxing for 2.5 
h and recrystallization from the mixture of DMF and ethanol (1:1): 1.77 g (68%) of white 
powder. was obtained mp 298-3000C; IR (KBr) (νmax/cm-1): 3300, 2200, 1670, 1590; 1H-
NMR (DMSO-d6) (δ ppm): 10.96 (s, 2H, Hamide), 8.11 (d, 4H, Harom., J = 8.24 Hz), 8.01 (d, 
4H, Harom., J = 8.24 Hz), 7.91 (s, 3H, Hpy); 
13C-NMR (DMSO-d6) (δ ppm): 164.9, 150.3, 
140.4, 138.4, 132.6, 128.9, 118.4, 114.3, 111.7; Anal. (C21H13N5O2) Calcd.: C, 68.66; H, 3.57; 
N, 19.06. Found: C, 68.52; H, 3.66; N, 19.17. 
                                                                                
4.1.14. N,N'-Di-(4-amidinobenzoyl)-(pyridine-2,6-di-yl)-amine hydrochloride (18) 
 Following the general procedure C, from 17 (1.05 g, 0.0029 mol) and after recrystallization 
from methanol: 0.24 (22%) of white powder. was obtained, mp 224-2280C; IR (KBr) 
(νmax/cm-1): 3200, 1670, 1590; 1H-NMR (DMSO-d6) (δ ppm): 10.91 (s, 2H, Hamide), 9.56 (s, 
4H, Hamidine), 9.33 (s, 4H, Hamidine), 8.16 (d, 4H, Harom., J = 8.31 Hz), 7.89-7.97 (m, 7H, 4Harom., 
3Hpy); 
13C-NMR (DMSO-d6) (δ ppm): Anal. (C21H21Cl2N7O2 x 2H2O) Calcd.: C, 49.42; H, 
4.94; N, 17.21. Found: C, 49.49; H, 5.30; N, 17.15. 
 
4.1.15. N,N'-Di-[4-(N''-isopropyl)amidinobenzoyl]-(pyridine-2,6-di-yl)-amine hydrochloride 
(19) 
 Following the general procedure C, from 17 (0.47 g, 0.0013 mol) and after recrystallization 
from the mixture of ethyl acetate and methanol (1:1): 0.16 g (28%) of white powder. was 
obtained, mp 230-2340C; IR (KBr) (νmax/cm-1): 3380, 3040, 1650, 1620, 1600; 1H-NMR 
(DMSO-d6) (δ ppm): 11.91 (s, 2H, Hamide), 9.54 (d, 2H, Hamidine, J = 7.68 Hz), 9.43 (s, 2H, 
Hamidine), 9.08 (s, 2H, Hamidine), 8.28-8.41 (m, 7H, 4Harom., 3Hpy), 7.79 (d, 4H, Harom., J = 8.97 
Hz), 4.05-4.07 (m, 2H, CHi-pr), 1.27 (d, 12H, CH3 i-pr, J = 6.32 Hz); 
13C-NMR (DMSO-d6) (δ 
ppm): 162.8, 161.3, 149.1, 143.1, 139.9, 129.1, 126.0, 124.0, 120.6, 45.1, 21.4; Anal. 
(C27H33Cl2N7O2 x 4H2O) Calcd.: C, 51.43; H, 6.55; N, 15.55. Found: C, 51.59; H, 6.85; N, 
15.20. 
 
4. 2. Spectroscopy and study of interactions with DNA/RNA 
 
The electronic absorption spectra were obtained on Varian Cary 100 Bio spectrometer, 
CD spectra on JASCO J815 spectrophotometer and fluorescence spectra on the Varian 
Eclipse fluorimeter, all in quartz cuvettes (1 cm). The spectroscopic studies were performed in 
aqueous buffer solution (pH = 7, sodium cacodylate buffer, I=0.05 mol dm-3). Under the 
experimental conditions absorbance of studied compounds was proportional to their 
concentrations. Polynucleotides were purchased as noted: poly A-poly U, poly G-poly C, poly 
dA-poly dT (Sigma), calf thymus (ct-) DNA (Aldrich). Polynucleotides were dissolved in 
sodium cacodylate buffer, I = 0.05 mol dm-3, pH=7. Calf thymus (ct-) DNA was additionally 
sonicated and ﬁltered through a 0.45 µm ﬁlter [26,27]. Polynucleotide concentration was 
determined spectroscopically [25] as the concentration of phosphates. Spectroscopic titrations 
were performed by adding portions of polynucleotide solution into the solution of the studied 
compound.  
Obtained data were corrected for dilution. Titration data were processed by Scatchard 
equation [21]. Values for Ks and n all have satisfactory correlation coefficients (>0.999). 
Thermal melting curves for DNA, RNA and their complexes with studied compounds were 
determined as previously described [27,28] by following the absorption change at 260 nm as a 
function of temperature. Absorbance of the ligands was subtracted from every curve, and the 
absorbance scale was normalized. The Tm values are the midpoints of the transition curves, 
determined from the maximum of the first derivative and checked graphically by the tangent 
method [27]. Tm values were calculated subtracting Tm of the free nucleic acid from Tm of 
the complex. Every Tm value here reported was the average of at least two measurements, 
the error in Tm is  0.5 °C.  
Ethidium bromide (EB) displacement assay: to a polynucleotide solution (c = 5  10–5 
mol dm–3) ethidium bromide (c = 5  10–6 mol dm–3) was added (r ([EB]/ [polynucleotide] = 
0.1), and quenching of the EB-polynucleotide complex fluorescence emission (ex = 520 nm, 
em = 550 - 700 nm) was monitored as function of c(EB)/c(compound). The given IC50 values 
present the ratio c(EB)/c(compound) = [Int(EB/polynucleotide) – Int(EBfree)] / 2, where 
Int(EB/ polynucleotide) is fluorescence intensity of EB/polynucleotide complex and 
Int(EBfree) is fluorescence intensity of the free ethidium bromide before polynucleotide is 
added. The compounds and their complexes with polynucleotides showed neither optical 
absorption nor fluorescence above 550 nm and did not interfere with the fluorescence of the 
free ethidium bromide. 
   
4.3. Antitumor evaluation Assays  
 
The HeLa (cervical carcinoma), MCF-7 (breast carcinoma), SW 620 and HCT116 
(colon carcinoma), MiaPaCa-2 (pancreatic carcinoma), Hep-2 (laryngeal carcinoma) and H 
460 (lung carcinoma) cells were cultured as monolayers and maintained in Dulbecco's 
modified Eagle's medium (DMEM), while the MOLT-4 (lymphoblastic leukemia) cells were 
cultured in RPMI medium both supplemented with 10% fetal bovine serum (FBS), 2mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in a humidified atmosphere with 
5% CO2 at 37˚C. 
 The growth inhibition activity was assessed as previously described [18]. The cells 
were inoculated onto standard 96-well microtiter plates on day 0. The cell concentrations 
were adjusted according to the cell population doubling time. Test agents were then added in 
five consecutive 10-fold dilutions (10-8 to 10-4 mol/l) and incubated for a further 72 hours. 
Working dilutions were freshly prepared from DMSO stock solutions (c = 1 × 10-2 mol/l) on 
the day of testing. After 72 hours of incubation, the cell growth rate was evaluated by 
performing the MTT assay, which detects dehydrogenase activity in viable cells. The 
absorbency (OD, optical density) was measured on a microplate reader at 570 nm.  
Each test point was performed in quadruplicate in at least two individual experiments. 
The results are expressed as IC50, which is the concentration necessary for 50% of inhibition. 
The IC50 values for each compound are calculated from dose-response curves using linear 
regression analysis by fitting the test concentrations that give PG values above and below the 
reference value (i.e. 50%). If, however, for a given cell line all of the tested concentrations 
produce PGs exceeding the respective reference level of effect (e.g. PG value of 50), then the 
highest tested concentration is assigned as the default value, which is preceded by a ">" sign. 
Each result is a mean value from three separate experiments. 
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Table 1. Electronic absorption data for compounds 5, 6, 9, 10, 13, 14, 18, and 19 a 
Compd. max / nm ε  103 / dm3 mol-1 cm-1 
5 295 22.4 
6 292 27.2 
9 312 52.0 
10 314 57.4 
13 292 37.3 
14 289 36.5 
 
18 
238 37.3 
300 21.3 
 
19 
236 58.3 
301 31.2 
a Sodium cacodylate/HCl buffer, I = 0.05 mol dm-3, pH = 7. 
 
Table 2. Tm values (°C)a of studied ds-polynucleotides at different ratios r at pH = 7 
(sodium cacodylate/HCl buffer, I = 0.05 mol dm-3). 
 rb 9 10 13 14 18 19 
ct-DNA 0.3 
0.5 
7.5 
-c 
5.6 
6.6 
6.7 
- c 
8.5 
10.3 
13.5 
15 
13.1 
14.5 
poly A-poly U 0.3 
0.5 
1.6 
- c 
4.5  
20.1 
~1.0 
- c 
3.1 
3.7  
~1.0 
18.7  
3.7 
5.7 
poly dA-poly dT 0.3 
0.5 
30.2 
- c 
29.5 
31.7 
20.4 
- c 
24.1 
25.5 
29.3 
30.9 
30.5 
32.2 
a  Error in Tm :  0.5°C; b r = [compound] / [polynucleotide]; c Not possible to determine due 
to precipitation 
 
 
Table 3. IC50-values
a for EB displacement from different ds-polynucleotides by diamidines 
(Sodium cacodylate/HCl buffer, I = 0.05 mol dm-3, pH = 7). 
 9 10 13 14 18 19 
ct-DNA 0.8 0.36 0.3 0.15 0.19 0.13 
poly A-poly U 1 0.03 0.47 0.17 0.5 0.07 
poly G-poly C 0.36 0.2 0.25 0.1 0.07 0.07 
poly dA-poly dT 2.1 2.23 1.6 1.37 1.7 2 
aRatio [EB]/[compound] at which 50% of EB fluorescence is quenched, meaning that 
approximately half of EB is displaced from its DNA complex. IC50 = [Int(EB-polyncleotide)-
Int(EBfree)]/2, where Int[EB-polynucleotide] is fluorescence intensity of EB-polynucleotide 
complex and Int(EBfree) fluorescence intensity of free EB before polynucleotide addition. 
 
 
 
Table 4. Inhibitory activities of compounds 3, 5, 6, 9, 10, and 11 on the growth of human 
tumor cells 
 
Compd. 
  IC50 a/ µM   
Hep-2 HeLa MiaPaCa-2 SW 620 MCF-7 
3 ≥100 47±22 >100 >100 32±9 
5 ≥100 ≥100 >100 >100 33±16 
6 >100 60±4 >100 >100 ≥100 
9 11±10 >100 53±39 >100 5±4 
10 5±2 50±30 79±3 4±3 4±2 
11  >100 >100 >100 >100 >100 
a IC50, the concentration that causes a 50% reduction of the cell growth 
 
 
 
Table 5. Inhibitory activities of compounds 13, 14, 18, and 19 on the growth of human tumor 
cells  
 
Compd. 
IC50 a/ µM 
Hep-2 HeLa MiaPaCa-2 SW 620 MCF-7 MOLT-4 HCT 116 H 460 
13 47±2 18±2 13±1 >100 >100 >100 >100 19±3 
14 30±14 53±47 >100 >100 32±0.2 >100 >100 >100 
18 21±11 19±12 13±0.06 >100 12±0.6 >100 67±30 17±2 
19 38±38 56±43 >100 >100 24±4 >100 >100 >100 
a IC50, the concentration that causes a 50% reduction of the cell growth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Captions 
 
Scheme 1. Reagents and conditions: i) dry DMF, dry THF, Et3N (9); dry toluene, Et3N (3, 5, 
10, 11); ii) 1. anhydrous EtOH, HCl(g), 2. anhydrous EtOH, RNH2, 3. anhydrous EtOH, 
HCl(g).  
 
Scheme 2. Reagents and conditions: i) dry DMF, dry THF, Et3N (13, 14); dry toluene, dry 
THF, Et3N (17); ii) 1. anhydrous EtOH, HCl(g), 2. anhydrous EtOH, RNH2, 3. anhydrous 
EtOH, HCl(g). 
 
 
Figure 1. Pentamidine, furamidine and new conformationally restricted derivatives. 
 
Figure 2. The normalized thermal denaturation experiments with poly dA-poly dT in the 
presence of compounds 9, 10, 13, 14, 18 and 19 at the ratio r([compound]/[polynucleotide]) = 0.3 
(sodium cacodylate/HCl buffer, I = 0.05 mol dm-3, pH 7). 
 
Figure 3. UV/Vis spectral changes of a) 9 (c = 1.0 x 10-5 mol dm-3) and b) 10 (c = 1.2 x 10-5 
mol dm-3) upon the addition of ct-DNA; (sodium cacodylate/HCl buffer, I = 0.05 mol dm-3, 
pH 7). 
 
Figure 4. Ethidium bromide (EB) assay: to EB solution, polynucleotides were added ([EB] / 
[polynucleotide] = 0.1), and quenching of EB-polynucleotide fluorescence emission was 
monitored as function of increasing [EB] / [compound]; Displacement of EB from its 
complexes with: a) ct-DNA, b) poly A-poly U; c) poly G-poly C, d) poly dA-poly dT; 
(sodium cacodylate/HCl buffer, I = 0.05 mol dm-3, pH 7). 
 
Figure 5. CD spectra of ds polynucleotides in the presence of compound 10 ; a) ct-DNA, b) 
poly A-poly U; c) poly G-poly C, d) poly dA-poly dT; (sodium cacodylate/HCl buffer, I = 
0.05 mol dm-3, pH 7).  
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